Trilogy Writing and Consulting Logo

Risk Management Plans and Summary for the Lay Reader

July 12, 2016 | Frankfurt, Germany

Trilogy hosted a discussion on every-day challenges involved in meeting the guideline on good pharmacovigilance practices (GVP), the challenge of writing and managing Risk Management Plans (RMPs), including the newly legislated Part VI.2 of the RMP (summary for the lay reader), and focused also on the potential changes and challenges posed by the updated guideline in consultation, together with our speakers:

  • Sven Schirp (Head of Global Pharmacovigilance Writing at Boehringer Ingelheim)
  • Dr. Lisa Chamberlain James (Senior Partner at Trilogy Writing & Consulting, UK)